Relevant Publications

  • Galbraith WM, Hobson WC, Giclas PC and Agrawal S. Complement Activation Following the Systemic Administration of Phosphorothioate Oligonucleotides in the Monkey. Antisense. 1994. 4(3):201-207.
  • Henry, SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Crooke R and Kornbrust DJ. Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action. J Pharmacology and Experimental Therapeutics. 1997. 281:810-818.
  • Henry SP, Beattie G, Yeh G, Chappel A, Giclas PC, Mortari A, Jagels MA, Kornbrust DJ and Levin AA. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002. Mov;2(12):1657-66.
  • Wen L, Atkinson JP and Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. 2004. 113:585-93
  • Tosca SM, Zwayer C, Johnson MJ, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2008 Sep 3.

Featured Research 

Severe Allergic Reactions and the EpiPen
New research indicates that young children suffer allergic reactions to food more frequently than doctors realized, and that more caregivers need know how to use an EpiPen.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.